Informace o publikaci

5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial


STRNAD Vratislav OTT Oliver J. HILDEBRANDT Guido KAUER-DORNER Daniela KNAUERHASE Helen MAJOR Tibor LYCZEK Jaroslaw GUINOT Jose Luis DUNST Jürgen MIGUELEZ Cristina Gutierrez ŠLAMPA Pavel ALLGÄUER Michael LÖSSL Kristina POLAT Bülent KOVÁCS György FISCHEDICK Arnt-René WENDT Thomas G. FIETKAU Rainer HINDEMITH Marion RESCH Alexandra KULIK Anna ARRIBAS Leo NIEHOFF Peter GUEDEA Fernando SCHLAMANN Annika PÖTTER Richard GALL Christine MALZER Martina UTER Wolfgang POLGÁR Csaba

Rok publikování 2016
Druh Článek v odborném periodiku
Časopis / Zdroj Lancet
Fakulta / Pracoviště MU

Lékařská fakulta

Obor Onkologie a hematologie
Popis Background In a phase 3, randomised, non-inferiority trial, accelerated partial breast irradiation (APBI) for patients with stage 0, I, and IIA breast cancer who underwent breast-conserving treatment was compared with whole-breast irradiation. Here, we present 5-year follow-up results. Methods We did a phase 3, randomised, non-inferiority trial at 16 hospitals and medical centres in seven European countries. 1184 patients with low-risk invasive and ductal carcinoma in situ treated with breast-conserving surgery were centrally randomised to either whole-breast irradiation or APBI using multicatheter brachytherapy. The primary endpoint was local recurrence. Analysis was done according to treatment received. This trial is registered with, number NCT00402519. Findings Between April 20, 2004, and July 30, 2009, 551 patients had whole-breast irradiation with tumour-bed boost and 633 patients received APBI using interstitial multicatheter brachytherapy. At 5-year follow-up, nine patients treated with APBI and five patients receiving whole-breast irradiation had a local recurrence; the cumulative incidence of local recurrence was 1.44% (95% CI 0.51-2.38) with APBI and 0.92% (0.12-1.73) with whole-breast irradiation (difference 0. 52%, 95% CI -0.72 to 1.75; p=0.42). No grade 4 late side-effects were reported. The 5-year risk of grade 2-3 late side-effects to the skin was 3.2% with APBI versus 5.7% with whole-breast irradiation (p=0.08), and 5-year risk of grade 2-3 subcutaneous tissue late side-effects was 7.6% versus 6.3% (p=0.53). The risk of severe (grade 3) fibrosis at 5 years was 0.2% with whole-breast irradiation and 0% with APBI (p=0.46). Interpretation The difference between treatments was below the relevance margin of 3 percentage points. Therefore, adjuvant APBI using multicatheter brachytherapy after breast-conserving surgery in patients with early breast cancer is not inferior to adjuvant whole-breast irradiation with respect to 5-year local control, disease-free survival, and overall survival.

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info